Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease. - Wikidata - wikimedia - TriplyDB

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

http://www.wikidata.org/entity/Q33394010

about

Synanthropic rodents as possible reservoirs of shigatoxigenic Escherichia coli strains Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence Shiga toxin pathogenesis: kidney complications and renal failure.Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.Renal and neurological involvement in typical Shiga toxin-associated HUS.A novel murine infection model for Shiga toxin-producing Escherichia coli.Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure.[Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease].Role of Shiga/Vero toxins in pathogenesis Complement, thrombotic microangiopathy and disseminated intravascular coagulation.Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury The ability of an attaching and effacing pathogen to trigger localized actin assembly contributes to virulence by promoting mucosal attachment.Renal failure in the recent 2011 Escherichia coli O104:H4 outbreak: a summary on up-to-date data.Identifying mechanisms by which Escherichia coli O157:H7 subverts interferon-γ mediated signal transducer and activator of transcription-1 activation.Recent advances in understanding enteric pathogenic Escherichia coli.Genomic comparison of Escherichia coli O104:H4 isolates from 2009 and 2011 reveals plasmid, and prophage heterogeneity, including shiga toxin encoding phage stx2 Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells Commensal E. coli Stx2 lysogens produce high levels of phages after spontaneous prophage induction.Glycolipid binding preferences of Shiga toxin variants.Comparative Characterization of Shiga Toxin Type 2 and Subtilase Cytotoxin Effects on Human Renal Epithelial and Endothelial Cells Grown in Monolayer and Bilayer Conditions.Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells.Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants.Ouabain protects against Shiga toxin-triggered apoptosis by reversing the imbalance between Bax and Bcl-xL.Retrograde trafficking of AB₅ toxins: mechanisms to therapeutics Diminazene aceturate: an antibacterial agent for Shiga-toxin-producing Escherichia coli O157:H7.Synchronous Disease Kinetics in a Murine Model for Enterohemorrhagic E. coli Infection Using Food-Borne Inoculation Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy.Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.Ouabain Protects Human Renal Cells against the Cytotoxic Effects of Shiga Toxin Type 2 and Subtilase Cytotoxin.Genotype Cluster Analysis in Pathogenic Escherichia coli Isolates Producing Different CDT Types.Enterohemorrhagic Escherichia coli O157:H7 Shiga toxins inhibit gamma interferon-mediated cellular activation Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Shiga Toxin Glycosphingolipid Receptors in Human Caco-2 and HCT-8 Colon Epithelial Cell Lines.Advances in our Understanding of the Pathogenesis of Hemolytic Uremic Syndromes.Thrombotic Microangiopathy and the Kidney.

P2860

Q21131304-72FC6158-444F-49CC-95E1-3CBB62AC2F59 Q27003178-2D90A519-4852-40EC-A93E-A8EA4B015A22 Q30411012-BA0B0F79-9466-47F8-9708-AB2E9CB15C6F Q33397541-249262B6-60EE-4250-B92E-B3800318042E Q33401572-51664AC4-0B9F-4011-98E3-9D1C6915A24C Q33403361-27A8A3EA-24A9-4C12-B996-C020014A2AFF Q33403695-32345E91-8D40-41EF-8606-67CCA1713D56 Q33404640-87AC3E74-36FB-4ACA-A94C-B2173FA325B4 Q33407861-BA816D38-2FE1-47BD-A8BF-819F0EDE3164 Q33409878-522F216B-4057-403E-883B-6257AEC691DE Q33415795-6740CE3D-A3E5-4F36-8266-5518FDFF5B8D Q33418419-089F9ACC-EFA4-4847-B524-31B542A57665 Q33419440-7B29F670-FC89-45C5-86B9-56D910CACC34 Q33420624-85753E0A-56C5-4959-B442-BC17004C8295 Q33433630-0DA948E7-4EE5-4FC5-B646-2A5F553DA412 Q34098076-A1E2089D-CB44-4F96-9EA3-C3800BD6295B Q34129271-882823A4-35F6-4B90-A53A-96572EAD89F3 Q34131136-C2940758-E7E2-4527-A6D0-F933C1DAC8CA Q34375210-70D13775-24A4-4BFE-A0ED-69C37824DE03 Q34469643-B18E0E7A-B3E9-4557-92AD-50B7E21EC6CE Q34922868-5911A3C8-FA20-4202-9FB5-0AE958FDB442 Q35042338-F9020EFA-C768-41DC-8999-D3F67B22789D Q35199053-9195EFD3-6642-49BC-8C09-A5F019D18466 Q36060108-AEC84545-1F27-4D51-BB18-A9CD0A46B6CE Q36744101-EFCFD6DD-3843-47BB-B779-E49C30CB6CFE Q36837884-5F902B0A-7A5B-4878-8CB0-AD5F4BCD7F10 Q37036097-F4858AF5-1492-477F-85EC-CFB1D487F69A Q37119923-469EFA70-B08F-4B9A-B3DE-ADBE9CAB7073 Q37171510-57D45C4A-57EB-46E4-81DB-FD988A1803B7 Q37354260-9D77B6F4-3F79-43B6-A671-FA8438F98986 Q37389490-075E4D3A-03E7-4E8A-8218-7C9F5EFAC8CC Q37954333-99AD2ECA-7CA5-44AA-9F87-D95CAFBB1C6C Q38024274-DBAF0111-44EC-482D-B1EE-7FCF77195BDA Q38674148-2C5AE8EC-8F67-4506-B732-5EF3A1FEBB88 Q39059706-BF9C70BF-9064-4992-A46E-EC887E5068CD Q39360310-45FE8397-0F7D-4394-9EDE-F1A34D91EDAB Q42086661-038DA748-1E62-4117-9A9E-3C44C313EB72 Q47121042-C22A2F53-EC51-454A-AC34-778522292486 Q49789113-9085F3AE-8393-40D4-83EF-B0D581B1EF1E Q50085453-C9ED4408-1126-4018-AB31-DE16943AD73B

P2860

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

http://www.wikidata.org/entity/Q33394010

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

@ast

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

@en

type

label

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

@ast

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

@en

prefLabel

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

@ast

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

@en

P1433

Q33394010-FE39DD83-C897-4F40-A611-9E8A1B3D973A

P1476

Q33394010-B87D10AD-13D7-441E-8858-CA3B6369ED3E

P2093

Q33394010-00D82454-C24F-4706-83E7-792C5AB08A1B

P2860

Q33394010-03C7E70A-B16A-46AE-BA89-BB06ECB30602

Q33394010-0692E894-0984-448B-9F19-FC7DE8CD1363

Q33394010-06C06B86-1726-4BBA-813F-0A40B51DE411

Q33394010-06D5D7F2-284F-49C2-8BEF-D041025C2ED7

Q33394010-08F93120-0C92-4B53-9CF7-792EFA7367B2

Q33394010-0B5F8E6B-79B0-46FB-B019-F1F5DA92B04E

Q33394010-0B989B13-2D3A-450F-B0B1-D2BEBB3FED32

Q33394010-0E61A6F1-20CC-4467-8CAB-DAB4506DF85A

Q33394010-10303A65-ABAE-4EB5-B1A3-C845B7895E24

Q33394010-10B25945-4166-428C-BB32-1505DB26FDE3

P304

Q33394010-A5339BDE-8874-4CEB-8BAE-90B12800ED15

P31

Q33394010-187B8458-32D5-48E3-97CB-8CE809B320F6

P356

Q33394010-1D820235-5036-4DE3-97CE-D57734253745

P433

Q33394010-98AF7632-AC47-476C-B63D-2458B5CB9477

P478

Q33394010-5D996DE3-1776-4EFD-B9A0-41D4A70D72A2

P577

Q33394010-9042BCAA-004C-4EA1-90F1-D092FE58A16A

P5875

Q33394010-D9F077E2-715A-44B8-BE3E-F084890E7464

P698

Q33394010-60AD1C36-3F7C-42A2-B32F-FA5666E0AD10

P921

Q33394010-1F8AD8CB-2075-4C15-96E5-1594CD24B189

P932

Q33394010-D8057425-5E97-40E3-98F7-63DD768EDBB8

P356

P1433

P1476

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

@en

P2093

Tom G Obrig

http://www.w3.org/2001/XMLSchema#string

P2860

Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome

Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections

VEGF inhibition and renal thrombotic microangiopathy

The molecular biology of thrombotic microangiopathy

Shiga toxin 2 targets the murine renal collecting duct epithelium

Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons.

Shiga toxin increases formation of clathrin-coated pits through Syk kinase

Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense

P304

2769-2794

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/TOXINS2122769

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49814158

http://www.w3.org/2001/XMLSchema#string

P698

21297888

http://www.w3.org/2001/XMLSchema#string

P921

Escherichia coli

P932

3032420

http://www.w3.org/2001/XMLSchema#string